Skip To Content

Thought leadership on the clinical impact on workers' compensation and auto no-fault.

Recent blog posts

September 29, 2020 · Clinical Team
The U.S. Food and Drug Administration (FDA) has issued a labeling change requiring the Boxed Warning and other precautions included in prescribing information to be updated for all benzodiazepines. Read more...
September 23, 2020 · Clinical Team
The U.S. Food and Drug Administration (FDA) announced that Perrigo Pharmaceutical Company issued a voluntary recall for all unexpired albuterol sulfate inhalation aerosol to the retail level. The September 21, 2020 recall announcement was issued due to the potential clogging of the inhaler, which could result in health risks to patients if they do not receive enough or any medication when using the inhaler. Read more...
September 14, 2020 · Clinical Team
The U.S. Food and Drug Administration (FDA) has issued a safety communication regarding the use of hot/cold therapy devices. The September 9, 2020 communication reminds patients and healthcare providers about the importance of following the instructions when providing cold therapy through a water-circulating hot/cold therapy device. Read more...
September 10, 2020 · Optum Workers' Comp and Auto No-fault
ODG has been making changes to treatment guidelines. Optum is following suit by changing some of our program parameters. Beginning September 23, 2020, Optum is lowering our opioid alerting parameter to 90 mg of oral morphine equivalents (morphine equivalent dose, or MED) for treating chronic pain. Read more...
August 13, 2020 · Optum Workers' Comp and Auto No-fault
A new injectable opioid analgesic, Olinvyk™ (oliceridine), was approved by the U.S. Food and Drug Administration (FDA) on August 7, 2020. Olinvyk is indicated to manage acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Read more...
August 03, 2020 · Clinical Connection team
In late July, the U.S. Food and Drug Administration (FDA) announced they are requiring manufacturers of all opioid analgesics and medications to treat opioid use disorder (OUD) to add recommendations about naloxone to the prescribing information and patient Medication Guides. Read more...
July 28, 2020 · Clinical Connection team
The U.S. Food and Drug Administration (FDA) recently added dexamethasone sodium phosphate to their approved list of medications that may be temporarily compounded during the COVID-19 pandemic. Read more...
     Next >>
Page 1 of 5

Subscribe today to receive our latest blogs, articles and more.

Subscribe now button

Download the latest
Pharmacy Resource Guide

Pharmacy Resource Guide